RE:RE:Wow factor still there It looks unlikely that mBC will advance into a Phase III trial without a checkpoint inhibitor (i.e. Avelumab). So that means there is no value proposition for the CPI company to make any offer, they'll just walk away...
All the pumping about valuation on here, has been about what Pela is worth to the CPI company, because if it enables the CPI to work in combo, whereas before it did not, it was potentially adding billions to that company's sales... if Pela + CPI adds no benefit, then there will be no deal, no buyout, an ONCY is still looking to find someone to fund the phase III... they are almost where they were five years ago...
did I mention that that Phase II started 11 years ago..??? This managment team is a liability to shareholders, as they failed to understand how Pela worked for 20 years.
That's why... glta